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Results: The patients included 23 male patients and 23 female patients 
with a median age of 62 years (mean age, 59.5 years; age range, 37-79 
years). Histologically, the specimens were classiﬁed into 13 cases of 
squamous cell carcinoma and 33 cases of adenocarcinoma. Never-
smokers made up 52.2% (24/46) of patients. EGFR overexpression was 
detected in 80.4% (37/46) of the tumors, and was observed exclusively 
in patients with partial response when compared to those with either 
stable or progressive disease (100% vs 76.3%; p=0.083). EGFR gene 
ampliﬁcation was found in 48.3% (14/29) of the tumors. EGFR protein 
expression showed signiﬁcant association with EGFR gene ampliﬁca-
tion (p=0.024). Median TTP was 6.7 months and OS was 22.6 months. 
OS was longer in female patients (p=0.003) and in patients with geﬁ-
tinib treatment (p=0.025), partial response (p=0.037), adenocarcinoma 
(p=0.007), and lower T (p=0.013). The patients with EGFR overexpres-
sion and/or gene ampliﬁcation had signiﬁcantly prolonged OS (24.4 vs 
12.4 months; p=0.005) and TTP (7.2 vs 3.4 months; p=0.083). Their 
stage tended to be lower (p=0.095). The multivariate analysis with Cox 
proportional hazards model revealed geﬁtinib therapy, sex, response, 
EGFR overexpression and gene ampliﬁcation as signiﬁcant prognostic 
factors (p=0.002, 0.048, 0.033, 0.023 and 0.042, respectively).
Conclusion: EGFR overexpression was associated with improved 
response to geﬁtinib therapy. EGFR protein expression in NSCLC was 
accompanied predominantly, but not exclusively, by gene ampliﬁcation. 
However, EGFR overexpression and/or gene ampliﬁcation was associ-
ated with TTP and OS, therefore, it is important to evaluate both EGFR 
protein expression and gene ampliﬁcation status in identifying patients 
most likely to beneﬁt from geﬁtinib therapy. 
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Background: Dysregulation of the AKT pathway is known to be 
important to develop many types of human cancer. However, little is 
known about the role of the AKT in neuroendocrine tumors of lung 
(NET). We sought to investigate p-Akt, PTEN, p-mTOR, p-TSC2, 
p-S6, and p-eIF4E in a large series of small cell lung cancer (SCLC), 
typical carcinoid (TC), atypical carcinoid (AC), and large cell neu-
roendocrine carcinoma (LCNEC). We also investigated the status of 
p-Erk1/2, which is a member of the RAS/MEK/ERK pathway, and 
interacts with the AKT pathway.
Methods: We immunohistochemically stained a tissue microarray with 
71 SCLC, 50 TC, 30 AC, and 29 LCNEC using antibodies to PTEN, 
p-AKT, p-mTOR, p-TSC2, p-S6, p-eIF4E, and p-Erk1/2. A score for 
each case was made based on distribution and intensity of staining and 
positive thresholds set according to clinical/molecular correlations. Fol-
low-up was available in 133 cases. Kaplan Meier survival analysis and 
chi-square statistics were made using JMP 5.0.
Results: In SCLC many correlations were found: negative p-Akt 
correlated with negative p-TSC2, p-S6, and p-eIF4E (p=0.025, 0.009, 
0.010): negative p-TSC2 correlated with negative p-mTOR, p-S6, and 
eIF4E (p=0.004, 0.007, and 0.011): negative p-Erk1/2 correlated with 
negative p-TSC2 and p-S6 (p=0.012, 0.033). Expression of PTEN in 
SCLC cases was attenuated compared to TC and AC (p<0.001). Over-
expression of p-Akt and p-S6 was observed in SCLC compared to in 
TC or AC (p=0.044, 0.010), whereas overexpression of p-TSC2 was in 
TC or AC comparing to SCLC (p<0.001). Although p-Akt was overex-
pressed cases where PTEN was preserved (p=0.002), cases with p-Akt 
overexpression and PTEN preserved staining were not correlated with 
survival compared to the other cases. Survival correlations were found 
for all NET and in SCLC with overexpression of eIF4E. Additionally 
cases with preserved staining of PTEN showed signiﬁcantly better 
survival among all NET.
Conclusion: Dysregulation of the AKT pathway is important in not 
only SCLC but other NETs with many interactions between down-
stream factors and prognostic correlations with p-eIF4E and PTEN.
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Introduction: Lung cancer is one of the leading cause of death.The 
incidence of lung cancer is up cropping even in the under developing 
country like Nepal (2), where the changing life style, addiction, occupa-
tion hazards, social and epidemiological factors are the major cause of 
cancer in Nepal. scientiﬁc research work claimed that p53 is detected as 
a signiﬁcance role to cause the cancer (3). Our present study encourage 
us due to the number of patient who are provision diagnose as cancer. 
Our research work is mainly focused on the total antioxidant status 
amongst the subjects provisionally diagnosed of lung cancer. 
Method: The study was conducted in lung cancer patients reports 
attending at Medicine and Surgery out patient department,different 
hospitals. This study was a form of pilot studies to asses the antioxidant 
status in cancer patients. A total of 108 subjects (male: 58, female 50) 
were chosen and an age-sex matched healthy controls of 108 subjects 
(male: 55, female 53). A four-day dietary recall was established to 
check the differences in dietary antioxidants intake in both groups. 5 ml 
of blood sample was collected after a written consent from the subjects 
and was stored at -22°C for further analysis. The total antioxidant, su-
per oxide dismutase, and glutathione peroxidase was measured adopt-
ing a ready-made kit procured from RANDOX, Germany. 
Results: Among the cancer patients the total antioxidant was relatively 
lowered and falling in lower borderline range to those observed in 
controls subjects. The results are shown in Table. No. I which is given 
below. 
Discussion: In the present study carried out on lung problem pa-
tients showed that the total antioxidants was lower in cancer patients 
compared to the control groups. This establishes the fact that lowering 
of antioxidants could be the most probable cause of lung cancer. The 
dietary antioxidants intake in the study subjects were similar to that of 
